Recent Updates
Recently added Catalysts

Testosterone Cypionate

Phase 2

Prostate Cancer | Small molecule | Oncology |Bayer AG|Last Updated: Aug 28, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment51

FDA Designations

No designations recorded

Clinical trial landscape

Testosterone Cypionate · 1 trial · 1 indication

Phase 2 1
NCT04558866Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)Prostate Cancer
COMPLETED51 Analytics
PHASE2COMPLETED
Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
Prostate CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Rate of Radiographic Progression-Free Survival (rPFS)
12 months

Defined as (at least one of the 3 criteria below): * Bone progression according to the Prostate Cancer Working Group 3 (PCWG3): * The first bone scan with ≥2 new lesions compared to baseline is observed \<12 weeks from randomization and is confirmed by a second bone scan taken ≥6 weeks later showing ≥2 additional new lesions (a total of ≥4 new lesions compared to baseline); * The first bone scan with ≥2 new lesions compared to baseline is observed ≥12 weeks from randomization and the new lesions are verified on the next bone scan ≥6 weeks later (a total of ≥2 new lesions compared to baseline). * Progression of soft tissue lesions measured by CT or MRI as defined in modified RECIST criteria. * •Death from any cause. The first bone scan with ≥2 new lesions compared to baseline is observed ≥12 weeks from randomization and the new lesions are verified on the next bone scan ≥6 weeks later (a total of ≥2 new lesions compared to baseline).

Secondary Endpoints

PSA decline ≥ 50% rate from baseline (PSA50)
54 weeks
Time to disease progression
54 weeks
Radiographic progression-free survival (rPFS)
54 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ExBAT ArmEXPERIMENTALTestosterone Cypionate 400 mg IM on Day 1 and Darolutamide 1,200mg/day (two 300 tablets every 12 hours) p.o. for 28 days, from day 29 to day 56 followed by a washout period of 7 days (63-day cycles), until loss of benefit (disease progression and/or limiting toxicity).

Interventions

NameTypeDescription
Testosterone CypionateDRUGOne administration every 63 cycles until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
DarolutamideDRUGDuring 4 weeks, from day 29 to day 56 of each 63-day cycle (+- 3 days) until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexMALE
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements. 2. Male aged 18 years and above. 3. Histol...

Countries:Brazil
Unlock Eligibility Criteria

Competitive Landscape -Prostate Cancer 252 trials